What 4 Analyst Ratings Have To Say About AVITA Medical
Portfolio Pulse from Benzinga Insights
Over the last quarter, AVITA Medical (NASDAQ:RCEL) received four somewhat bullish analyst ratings with no bearish or indifferent ratings. The 12-month price targets for RCEL suggest an average target of $22.75, with a high of $26.00 and a low of $19.00. This average is a slight decrease from the previous target of $23.00. Analysts rate stocks typically once per quarter based on various research methods and their ratings reflect their opinions on the stock's potential.
November 21, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AVITA Medical has received somewhat bullish ratings from analysts, with an average 12-month price target of $22.75, indicating a slight decrease from the previous target of $23.00.
The somewhat bullish ratings from analysts suggest a positive sentiment towards RCEL, which could lead to a short-term increase in its stock price. The slight decrease in the average price target may temper expectations but does not significantly alter the overall positive outlook.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100